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The Janus Face of VEGF Inhibitors*Rhian M. Touyz, MBBCH, PHD, Ninian N. Lang, MBCHB, PHDV ascular endothelial growth factor (VEGF) in-hibitors (VEGFIs), through their antiangio-genic actions, have transformed the
landscape of cancer therapy by improving clinical
outcomes and patient survival. These drugs are
among the most widely prescribed for solid tumors
(1,2) and retinopathy (3), and there is growing interest
in their use for other diseases such as psoriasis (4).
However, with the benefits of VEGFIs are unwanted
effects, in particular blood pressure (BP) elevation.
This class effect has been observed in all VEGFI
drug trials. In the most striking example, hyperten-
sion was identified in 87% of patients after only
1 week of cediranib treatment (5). Considering the
vascular target of VEGFIs, their association with car-
diovascular on-target side effects is not surprising
(6). BP elevation, which occurs rapidly, within hours
to days, reflects effective inhibition of VEGF signaling
and accordingly has been considered a biomarker of
tumor responsiveness (6,7).
Although there is unambiguous experimental and
clinical evidence that VEGFIs cause hypertension, the
pathophysiology and underlying molecular mecha-
nisms remain elusive. In addition, there is a paucity
of clinical information on how best to diagnose and
treat VEGFI-mediated cardiovascular toxicities, with
current practice relying on trial data. Oncology trials
tend to report hypertension as a categorical phe-
nomenon, relying on frequently changing definitions
provided by the Common Terminology Criteria forISSN 2666-0873
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pertension guidelines, which currently recommend
tight BP control with targets as low as 130/80 mm Hg
(8,9). Whether these lower BP targets are applicable
to VEGFI-treated cancer patients is unknown. Also, it
is unclear whether enforcing strict BP targets is
appropriate in this population if this means VEGFI
dose reduction, treatment interruption, or drug
cessation with consequent suboptimal cancer
response. On the other hand, patients receiving
VEGFIs may be at increased risk of end-organ com-
plications of hypertension. In particular, direct
myocardial toxicity of VEGFIs and increased afterload
as a consequence of hypertension may predispose to
left ventricular systolic dysfunction and heart failure
(10). Posterior reversible encephalopathy syndrome,
although rare, is another potential complication, as
are nephropathy and renal failure, especially in the
context of renal cancer (6,10). Hypertension is not
only a problem with systemic VEGFIs but may also be
a concern with local treatment, as suggested by a few
studies demonstrating worsening hypertension and
nephrotoxicity in patients treated with intravitreal
VEGFI therapy for retinopathy (11–13). Preventing
these complications, or at least intervening at an
early and potentially reversible phase, should be the
goal of management to allow the continuation of
VEGFI therapy at optimum doses for maximum anti-
cancer effect (6,14) (Figure 1).
Notwithstanding the uncertainties of applying
population-based thresholds for the diagnosis and
treatment of hypertension, the absolute rise in BP
after starting VEGFIs may be as important, if not more
so. The Cardiovascular Toxicities Panel of the
National Cancer Institute recommends: 1) formal
cardiovascular risk assessment before commencing
VEGFI treatment; and 2) initiation of antihyperten-
sive therapy in patients with a rise in diastolic BP of
>20 mm Hg, even in those who would conventionallyhttps://doi.org/10.1016/j.jaccao.2019.08.010























Ideal management of patients should balance antiangiogenic and cardiovascular toxicities so that anticancer treatment is optimized in the
absence of hypertension and cardiovascular disease. BP ¼ blood pressure; CVD ¼ cardiovascular disease; Rx ¼ prescription; VEGFI ¼ vascular
endothelial growth factor inhibitor.
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38be considered normotensive (14). These recommen-
dations are based on expert opinion rather than evi-
dence, as reflected by the focus on diastolic BP rather
than systolic BP, which is the element associated with
cardiovascular events and the component that major
hypertension guidelines emphasize (8,9). The most
effective agent for reduction of VEGFI-induced BP
rise is also undefined, and other than the avoidance
of nondihydropyridine calcium channel blockers
(CCBs), no class is currently recommended over
another (14). Nondihydropyridine CCBs inhibit cyto-
chrome P450 3A4, the enzyme that metabolizes
VEGFIs, leading to potentially high VEGFI plasma
levels, which may aggravate VEGFI-induced hyper-
tension (7).SEE PAGES 14 AND 24With the upsurge of VEGFIs as part of modern
chemotherapy protocols, the challenges to effectively
manage cardiovascular toxicities increase (1). Unless
gaps in knowledge are addressed and underlying
mechanisms better understood, the clinical burden of
cardiovascular toxicities in VEGFI-treated patients
will continue to grow. Tackling some of these
challenges are 2 studies in this issue of JACC:
CardioOncology, which provide insights into VEGFI-
associated BP elevation by retrospective analysis of
data from real-world American patients treated at 2
large oncology centers.Waliany et al. (15) provide a robust analysis of the
Stanford Renal Cancer Database to describe the
magnitude and timing of VEGFI-associated BP rise in
228 patients before and during treatment with
tyrosine kinase inhibitors of VEGF. In support of
previous studies, they confirmed that VEGFIs cause
an increase in BP, with axitinib having the greatest
potency. CCBs and potassium-sparing diuretic drugs
were the most effective antihypertensive agents in
these patients. An important finding in this study
that deserves more attention is the lack of effect of
inhibitors of the renin angiotensin aldosterone sys-
tem (RAAS). Neither angiotensin-converting enzyme
(ACE) inhibitors nor angiotensin receptor blockers
(ARBs) lowered BP in VEGFI-induced hypertension
in this study (15). This cannot be attributed to
ethnicity factors because only 3.1% of patients were
African Americans, who are typically less responsive
to RAS inhibitors than whites.
The second paper in this issue, by Bottinor et al.
(16), interrogated the database of patients in the
Vanderbilt electronic health record and hypothesized
that antihypertensive therapy with RAAS inhibitors
(ACE inhibitors, ARBs, aldosterone antagonists, or
renin inhibitors) mitigates VEGFI-mediated hyper-
tension more effectively than other antihypertensive
drugs. They studied 1,013 subjects and, similar
to other studies, reported a clear relationship be-
tween VEGFI and development or aggravation of
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39hypertension. The BP increase during VEGFI treat-
ment in the Vanderbilt cohort was lowest in patients
treated at baseline with RAAS inhibitors versus CCB
and diuretic agents. Although both papers in this
issue (15,16) are retrospective studies, and both are
based on robust information from large databases,
conclusions about RAAS inhibition in the manage-
ment of VEGFI-related hypertension are divergent.
Multiple factors likely contribute to this, including
the experimental design, baseline characteristics of
patient cohorts, type of cancer (renal versus non-
renal), timing of antihypertensive therapy (pre- or
post-commencement of VEGFI treatment), and
possibly the lack of involvement of the RAAS in the
pathophysiology of VEGFI-induced hypertension.
This is supported by preclinical and clinical studies
showing: 1) no change in plasma renin or aldosterone
levels in cancer patients treated with sorafenib (17);
2) decreased plasma renin activity and reduced renin
concentration with no change in aldosterone levels in
cancer patients treated with sunitinib (18); and
3) decreased renin expression and reduced aldoste-
rone urinary excretion in mice treated with a mono-
clonal antibody targeting the major VEGF receptor,
VEGFR2 (19). These studies have clinical significance
because they suggest that targeting the RAAS might
not be the preferred antihypertensive treatment
strategy in VEGFI-induced hypertension, a notion
supported by findings in the Stanford Renal Cancer
cohort (15).
Several other important points are highlighted by
the 2 studies in this issue of JACC: CardioOncology
(15,16). Patients receiving VEGFIs for cancer therapy
have substantial baseline cardiovascular comorbidity.
Exacerbation of hypertension occurs in the majority,
and there is now further real-world evidence to
reinforce this point and, in particular, to intensify BP
surveillance during the first 4 to 6 weeks of VEGFI
therapy (1,15,16). This may be even more pertinent
with more selective agents such as axitinib. However,
even after the identification and initial treatment of
the VEGFI-associated BP rise, current strategies are
not good enough to return BP to baseline during
VEGFI treatment. Although both studies raise ques-
tions about the most efficacious drug to prevent or
treat VEGFI-associated hypertension we still do not
have a robust answer, and in particular, the effec-
tiveness of ACE inhibitors and ARBs in these patients
is unclear. Optimal antihypertensive therapy has not
yet been defined, and accordingly, the selection of
classes of antihypertensive drugs should be based onparticular comorbidities and cancer types in individ-
ual patients.
Furthermore, BP targets from the population as a
whole are extrapolated to the VEGFI-treated cancer
population. Whether this is appropriate or not is un-
clear, especially since the cancer population may be
more susceptible to end-organ effects because of the
sudden nature of the BP rise coupled with the direct
toxic effects of VEGFIs on the vasculature, myocar-
dium, and kidneys (6). On the other hand, evidence-
based BP thresholds at which VEGFI dose reduction
or interruption should occur are still required. These
are needed to ensure that this is only done when
there is a genuine risk of cardiovascular morbidity
becoming more prescient than the index cancer. In
addition to defining the optimum agent for the pre-
vention and treatment of the VEGFI-associated BP
rise, it is of particular importance to identify those
drugs that might provide added value over and above
the reduction of BP per se in order to provide addi-
tional cardioprotective and renoprotective effects. It
is as important to identify antihypertensive drugs
that are not effective and that should probably be
avoided.
Unless adequately powered randomized controlled
trials to assess effects of different antihypertensive
drugs in the prevention or treatment of VEGFI-
associated hypertension are conducted, clinical
treatment will remain suboptimal, and management
will rely on expert opinion rather than evidence.
Trials should have clinically relevant endpoints that
address the control of BP and its target organ effects
(left ventricular systolic dysfunction and renal
dysfunction) versus cancer outcomes, including
VEGFI dose reduction and treatment interruption.
The field, although advancing, is still in its infancy
regarding the understanding of the underlying
mechanisms of VEGFI-induced hypertension and
evidence-based best clinical practice. Clinical de-
cisions and research questions that rely so heavily on
understanding the balance between cardiovascular
risk and optimum cancer care will only be adequately
tackled by continued and increasing cardiovascular-
oncology collaboration.
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